PeptideStack
5.2kquestions
20kanswers
220users

How comparable are mazdutide and semaglutide on the evidence available?

Asked 22 Feb 2025Modified 17 months agoViewed 6.4k times
13

Numbers first: mazdutide · semaglutide.

I want to know what the trade-off actually is rather than which option is fashionable.

I would rather have a defensible reason than a marginal improvement.

So which one, and on what grounds?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionssemaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

360 questionstirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

162 questions
shareeditfollowflag
SL
askedsecond_lot11k1522 Feb 2025
7Do you have a reference for the last claim? Not disputing it, just want to read it. – linnea_wahlberg 2 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 6.4k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.